Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Medicinal Chemistry|February 22, 2008
2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonistsYuhpyng L Chen, R Scott Obach, John Braselton, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 22, 2016
Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746Jean-Dominique Gallezot, Beata Planeta, Nabeel Nabulsi, et al.Journal of Medicinal Chemistry|July 13, 2011
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)Patrick R Verhoest, Aarti Sawant Basak, Vinod Parikh, et al.Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.Journal of Medicinal Chemistry|September 15, 2012
Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's diseaseMichael A Brodney, David E Johnson, Aarti Sawant-Basak, et al.Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.Journal of Medicinal Chemistry|June 3, 2017
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A InhibitorChristopher J Helal, Eric P Arnold, Tracey L Boyden, et al.Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.Pageof 3